MedTrace Logo

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

NCT02838836 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 620

Last updated 2026-05-01

No results posted yet for this study

Summary

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies.

Conditions

Interventions

PROCEDURE

Study sample collection

Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery

Sponsors & Collaborators

  • University of Missouri-Columbia

    lead OTHER

Principal Investigators

  • Jussuf T Kaifi, MD, PhD · Ellis Fischel Cancer Center, University of Missouri

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2027-12-01
Completion
2027-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02838836 on ClinicalTrials.gov